Imprivata Enterprise Access Management now offers facial recognition, AI-powered behavioral analytics, and high-assurance identity verification to further streamline clinical access, improve ...
Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of ...
EAGLE, Idaho, March 16, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, ...
Tobias Burkhardt’s Paretofit Reports 98.1% Success Rate Across 169 Entrepreneur Coaching Engagements
Paretofit, founded by Tobias Burkhardt, reports a 98.1% documented success rate across 169 completed coaching engagements with entrepreneurs, founders, and self-employed professionals in the DACH ...
(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...
Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that new data demonstrating the prognostic value of the Genomic Prostate ...
March 2026, CMR Surgical (“CMR”), the global surgical robotics company, today announced its participation in NVIDIA’s Physical AI healthcare robotics initiative, unveiled at NVIDIA GTC. As part of the ...
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of ...
Cash Position: Black Diamond ended 2025 with approximately $128.7 million in cash, cash equivalents, and investments compared to $98.6 million as of December 31, 2024. Net cash provided by operations ...
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and ...
CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseases Appointed industry veteran Lucinda Warren as Chief Financial and Business Officer Raised net proceeds of ...
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results